Immune-checkpoint inhibitors (ICIs), such as the blocking antibodies of programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have brought considerable clinical benefits to cancer patients. Here, CTLA4 is linked to cancer.